NASDAQ$CSCIF
Aeterna Zentaris Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
COSCIENS Biopharma Q2 revenue rises 18% to $2.7M but net loss widens to $2.7M on restructuring costs
COSCIENS Biopharma reported Q2 2025 results with revenue of $2.7 million, up 18% from $2.3 million a year ago, driven by active-ingredient sales. The company posted a net loss of $2.7 million for the quarter and $6.4 million for the first half, as operating expenses remained elevated amid a strategic turnaround. Management completed a zero-based budgeting reset that cut Q2 opex 27% versus prior year and announced plans to voluntarily delist from Nasdaq while maintaining its TSX listing. The company is assessing commercialization options for its nutraceutical pipeline and Macrilen growth hormone diagnostic franchise.
- Q2 revenue of $2.7M (+18% YoY); H1 revenue $4.2M versus $4.4M prior year
- Q2 net loss widened to $2.7M from $1.4M; H1 net loss $6.4M versus $2.8M
- Zero-based budgeting cut Q2 operating expenses 27% YoY; 27% headcount reduction post quarter-end
- Board approved voluntary Nasdaq delisting expected effective ~September 5, 2025
- Active-ingredient segment drove revenue growth; pharmaceutical Macrilen pediatric trial failed primary endpoint
Headline financials
Revenue & EPS history
Aeterna Zentaris · Revenue · Quarterly
$2.75M
Revenue by segment
Aeterna Zentaris · $2.75M total across 2 segments · Q2 2025
- Active Ingredients$2.42M—87.9%
- Pharmaceutical$332K—12.1%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
+0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+0.3%
Avg return
30 days after
42%
22 / 52 earnings
Positive
+43.3%
Q1 2020
Best reaction
-13.1%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | +0.0% | -24.9% | -25.7% | |
| Q1 2025 | +0.0% | +0.3% | +2.2% | |
| Q4 2025 | +1.4% | +0.4% | +26.3% | |
| Q3 2024 | -10.2% | -3.3% | -13.2% | |
| Q1 2024 | +3.0% | -10.5% | -36.1% | |
| Q2 2024 | +3.0% | -10.5% | -36.1% | |
| Q4 2023 | +9.5% | +4.5% | -2.0% | |
| Q3 2023 | -3.7% | +2.0% | +46.7% | |
| Q2 2023 | +0.0% | +1.4% | -15.6% | |
| Q1 2023 | -1.9% | -6.4% | -6.4% | |
| Q4 2022 | -0.4% | +0.4% | +16.6% | |
| Q3 2022 | +2.8% | -8.5% | +1.5% | |
| Q2 2022 | +5.0% | +10.0% | -5.2% | |
| Q1 2022 | +4.2% | -17.4% | -17.4% | |
| Q4 2021 | +1.5% | +2.8% | -16.7% | |
| Q3 2021 | -1.1% | -4.8% | -35.5% | |
| Q2 2021 | +3.4% | +2.8% | +2.8% | |
| Q1 2021 | -8.7% | -11.5% | -16.3% | |
| Q4 2020 | +11.8% | +2.7% | -14.5% | |
| Q3 2020 | -5.4% | +0.0% | +31.3% | |
| Q2 2020 | +7.6% | +15.2% | -13.0% | |
| Q1 2020 | +43.3% | +36.4% | +49.4% | |
| Q4 2019 | -6.9% | -14.5% | +47.3% | |
| Q3 2019 | +1.9% | -1.0% | -16.5% | |
| Q2 2019 | -4.0% | -6.3% | -16.5% | |
| Q1 2019 | -10.8% | -15.6% | -34.9% | |
| Q4 2018 | -3.1% | +11.0% | -6.9% | |
| Q3 2018 | -13.1% | -4.6% | +55.7% | |
| Q2 2018 | -2.4% | -6.5% | -12.1% | |
| Q1 2018 | -4.3% | -4.3% | +12.3% | |
| Q4 2017 | -9.6% | -17.9% | +3.1% | |
| Q3 2017 | +4.2% | +5.8% | +18.0% | |
| Q2 2017 | +13.3% | +15.0% | +2.2% | |
| Q1 2017 | -5.7% | -5.6% | +22.5% | |
| Q4 2016 | +1.7% | +0.0% | +2.8% | |
| Q3 2016 | -1.4% | +0.0% | +5.7% | |
| Q2 2016 | -1.7% | +2.8% | +6.3% | |
| Q1 2016 | +9.4% | — | — | |
| Q4 2015 | -3.0% | — | — | |
| Q3 2015 | -5.2% | — | — | |
| Q2 2015 | -13.0% | — | — | |
| Q1 2015 | -5.9% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2014 | +12.2% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | +3.7% | — | — | |
| Q2 2013 | +4.2% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q2 2010 | -11.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro